AI model using daily step counts predicts unplanned hospitalizations during cancer therapy

byAmerican Society for Radiation OncologyCredit: Pixabay/CC0 Public DomainAn artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unp

Updated on: January 04,2024

AI model using daily step counts predicts unplanned hospitalizations during cancer therapy

byAmerican Society for Radiation OncologyCredit: Pixabay/CC0 Public DomainAn artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unp

Updated on:January 04,2024

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on: November 02,2023

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on:November 02,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on: October 24,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on:October 24,2023

Cost of cancer treatment can impact health of survivors

byMedical College of Georgia at Augusta UniversityDrs. Steven Coughlin, from left, Jorge Cortes and Biplab Datta. Credit: Michael Holahan, Augusta UniversityA significant number of people who ha

Updated on: December 18,2023

Cost of cancer treatment can impact health of survivors

byMedical College of Georgia at Augusta UniversityDrs. Steven Coughlin, from left, Jorge Cortes and Biplab Datta. Credit: Michael Holahan, Augusta UniversityA significant number of people who ha

Updated on:December 18,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on: October 17,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on:October 17,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on: December 21,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on:December 21,2023

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on: October 12,2023

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on:October 12,2023

New insights into colorectal cancer and E. coli

by Béatrice St-Cyr-Leroux,University of MontrealclbA and bft detection. a clbA and b bft presence in DNA extracted from fecal samples were detected using conventional qualitative PCR. M: marker;

Updated on: December 17,2023

New insights into colorectal cancer and E. coli

by Béatrice St-Cyr-Leroux,University of MontrealclbA and bft detection. a clbA and b bft presence in DNA extracted from fecal samples were detected using conventional qualitative PCR. M: marker;

Updated on:December 17,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on: October 17,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on:October 17,2023

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Updated on: October 15,2023

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Updated on:October 15,2023

As cancer survival rates are improving, heart problems in survivors are becoming more common

by Sean Tan,Monash UniversityCredit: Pixabay/CC0 Public DomainThe soft beeping of medical devices deepens the silence of the operating theater waiting room. Lying between monitors and intravenou

Updated on: January 04,2024

As cancer survival rates are improving, heart problems in survivors are becoming more common

by Sean Tan,Monash UniversityCredit: Pixabay/CC0 Public DomainThe soft beeping of medical devices deepens the silence of the operating theater waiting room. Lying between monitors and intravenou

Updated on:January 04,2024